Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jan;21(1):4-7.
doi: 10.1016/j.bbmt.2014.09.017. Epub 2014 Sep 30.

Recommendations for donor human leukocyte antigen assessment and matching for allogeneic stem cell transplantation: consensus opinion of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN)

C Alan Howard  1 , Marcelo A Fernandez-Vina  2 , Frederick R Appelbaum  3 , Dennis L Confer  4 , Steven M Devine  5 , Mary M Horowitz  6 , Adam Mendizabal  7 , Ginna G Laport  8 , Marcelo C Pasquini  6 , Stephen R Spellman  9
Affiliations

Recommendations for donor human leukocyte antigen assessment and matching for allogeneic stem cell transplantation: consensus opinion of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN)

C Alan Howard et al. Biol Blood Marrow Transplant. 2015 Jan.

Abstract

The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) conducts large, multi-institutional clinical trials with the goal of improving the outcomes of hematopoietic cell transplantation (HCT) for patients with life-threatening disorders. Well-designed HCT trials benefit from standardized criteria for defining diagnoses, treatment plans, and graft source selection. In this perspective, we summarize evidence supporting criteria for the selection of related and unrelated adult volunteer progenitor cell donors or umbilical cord blood units. These standardized criteria for graft source selection have been adopted by the BMT CTN to enhance the interpretation of clinical findings within and among future clinical protocols.

Keywords: Allogeneic transplantations; Cord blood donor; Recipient; Related donor; Unrelated donor.

PubMed Disclaimer

References

    1. Pasquini MC, Wang Z. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides. 2013 Available at: http://www.cibmtr.org.
    1. Ballen KK, King RJ, Chitphakdithai P, et al. The National Marrow Donor Program 20 Years of Unrelated Donor Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2008;14(9):2–7. - PubMed
    1. Luznik L, O'Donnell PV, Symons HJ, et al. HLA-Haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14:641–650. - PMC - PubMed
    1. Shaw PJ, Kan F, Woo Ahn K, Spellman SR, et al. Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors. Blood. 2010;116(19):4007–4015. - PMC - PubMed
    1. Valcárcel D, Sierra J, Wang T, et al. One-antigen mismatched related versus HLA-matched unrelated donor hematopoietic stem cell transplantation in adults with acute leukemia: Center for International Blood and Marrow Transplant Research results in the era of molecular HLA typing. Biol Blood Marrow Transplant. 2011;17(5):640–648. - PMC - PubMed

Publication types